US 11,858,988 B2
Antibodies specific for claudin 6 (CLDN6)
Ugur Sahin, Mainz (DE); Özlem Türeci, Mainz (DE); Michael Koslowski, Frankfurt (DE); Korden Walter, Wiesbaden (DE); Stefan Woll, Nackenheim (DE); Maria Kreuzberg, Mainz (DE); Bernd Hubner, Munich (DE); and Michael Erdeljan, Hochheim am Main (DE)
Assigned to Ganymed Pharmaceuticals GmbH, Mainz (DE); and Johannes Gutenberg-Universität Mainz, Mainz (DE)
Filed by Ganymed Pharmaceuticals GmbH, Mainz (DE); and Johannes Gutenberg-Universitat Mainz, Mainz (DE)
Filed on Jul. 7, 2020, as Appl. No. 16/922,179.
Application 16/922,179 is a continuation of application No. 15/885,454, filed on Jan. 31, 2018, granted, now 10,745,477.
Application 15/885,454 is a continuation of application No. 15/133,783, filed on Apr. 20, 2016, granted, now 9,932,401, issued on Apr. 3, 2018.
Application 15/133,783 is a continuation of application No. 13/503,461, granted, now 9,487,584, issued on Nov. 8, 2016, previously published as PCT/EP2010/006888, filed on Nov. 11, 2010.
Claims priority of provisional application 61/361,618, filed on Jul. 6, 2010.
Claims priority of provisional application 61/260,202, filed on Nov. 11, 2009.
Claims priority of application No. 09014136 (EP), filed on Nov. 11, 2009; and application No. 10006956 (EP), filed on Jul. 6, 2010.
Prior Publication US 2020/0339677 A1, Oct. 29, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 5/10 (2006.01); C12N 15/00 (2006.01); C12N 15/09 (2006.01); C12N 15/13 (2006.01); C07K 16/02 (2006.01); A61K 39/00 (2006.01); C12N 15/63 (2006.01); C12N 5/16 (2006.01)
CPC C07K 16/02 (2013.01) [C07K 16/30 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C12N 5/10 (2013.01); C12N 5/16 (2013.01); C12N 15/00 (2013.01); C12N 15/09 (2013.01); C12N 15/63 (2013.01); C12N 2510/00 (2013.01); C12N 2800/00 (2013.01)] 24 Claims
 
1. A method of producing a single chain anti-CLDN6 antibody that binds to CLDN6, the method comprising the steps of:
a. culturing a host cell transformed with an expression construct comprising a nucleic acid sequence, said sequence encoding a polypeptide chain of a single chain anti-CLDN6 antibody comprising an antibody heavy chain variable region and an antibody light chain variable region under conditions in which the host cell expresses the single chain antibody; and
b. harvesting a preparation of the single chain antibody expressed by the cell;
wherein:
(i) the antibody heavy chain variable region comprises the heavy chain HCDR1, HCDR2, and HCDR3 regions of SEQ ID NO: 34 and the antibody light chain variable region comprises the light chain LCDR1, LCDR2, and LCDR3 regions of SEQ ID NO: 35,
wherein HCDR1 consists of amino acid sequence GYSFTGYT (SEQ ID NO: 47) identified within SEQ ID NO: 34, HCDR2 consists of amino acid sequence INPYNGGT (SEQ ID NO: 54) identified within SEQ ID NO: 34, and HCDR3 consists of amino acid sequence ARDYGYVLDY (SEQ ID NO: 55) identified within SEQ ID NO: 34, and wherein LCDR1 consists of amino acid sequence SSVSY (SEQ ID NO: 56) identified within SEQ ID NO: 35, LCDR2 consists of amino acid sequence STS (SEQ ID NO: 53) identified within SEQ ID NO: 35, and LCDR3 consists of amino acid sequence QQRSIYPPWT (SEQ ID NO: 57) identified within SEQ ID NO: 35;
(ii) the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 36 and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO: 37;
(iii) the antibody heavy chain variable region comprises the heavy chain HCDR1, HCDR2, and HCDR3 regions of SEQ ID NO: 38 and the antibody light chain variable region comprises the light chain LCDR1, LCDR2, and LCDR3 regions of SEQ ID NO: 39,
wherein HCDR1 consists of amino acid sequence GYSFTGYT (SEQ ID NO: 47) identified within SEQ ID NO: 38, HCDR2 consists of amino acid sequence INPYNGGI (SEQ ID NO: 60) identified within SEQ ID NO: 38, and HCDR3 consists of amino acid sequence ARDFGYVLDY (SEQ ID NO: 61) identified within SEQ ID NO: 38, and wherein LCDR1 consists of amino acid sequence SSVSY (SEQ ID NO: 56) identified within SEQ ID NO: 39, LCDR2 consists of amino acid sequence STS (SEQ ID NO: 53) identified within SEQ ID NO: 39, and LCDR3 consists of amino acid sequence QQRSTYPPWT (SEQ ID NO: 62) identified within SEQ ID NO: 39; or
(iv) the antibody heavy chain variable region comprises the heavy chain HCDR1, HCDR2, and HCDR3 regions of SEQ ID NO: 40 and the antibody light chain variable region comprises the light chain LCDR1, LCDR2, and LCDR3 regions of SEQ ID NO: 41,
wherein HCDR1 consists of amino acid sequence GYSFTGYT (SEQ ID NO: 47) identified within SEQ ID NO: 40, HCDR2 consists of amino acid sequence INPYNGGS (SEQ ID NO: 63) identified within SEQ ID NO: 40, HCDR3 consists of amino acid sequence ARDYGYVFDY (SEQ ID NO: 64) identified within SEQ ID NO: 40, LCDR1 consists of amino acid sequence SSVNY (SEQ ID NO: 65) identified within SEQ ID NO: 41, LCDR2 consists of amino acid sequence STS (SEQ ID NO: 53) identified within SEQ ID NO: 41, and LCDR3 consists of amino acid sequence QQRNNYPPWT (SEQ ID NO: 66) identified within SEQ ID NO: 41.